A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis
Small,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 19, 2025
Abstract
This
study
advances
sustainable
pharmaceutical
research
for
endometriosis
by
developing
in
vitro
3D
cell
culture
models
of
endometriotic
pathophysiology
that
allow
antifibrotic
drug
candidates
to
be
tested.
Fibrosis
is
a
key
aspect
endometriosis,
yet
current
it
remain
limited.
work
aims
bridge
the
translational
gap
between
fibrosis
and
preclinical
testing
non‐hormonal
candidates.
When
grown
matrix
sustainably
produced
silk
protein
functionalized
with
fibronectin‐derived
adhesion
motif
(FN‐silk),
endometrial
stromal
epithelial
cells
respond
transforming
growth
factor
beta‐1
(TGF‐β1)
physiological
manner
as
probed
at
messenger
RNA
(mRNA)
level.
For
cells,
this
response
TGF‐β1
not
observed
spheroids,
while
spheroids
behave
similarly
FN‐silk
networks.
Pirfenidone,
an
approved
treatment
idiopathic
pulmonary
fibrosis,
reverses
TGF‐β1‐induced
upregulation
mRNA
transcripts
involved
fibroblast‐to‐myofibroblast
transdifferentiation
networks,
supporting
pirfenidone's
potential
repurposed
therapy.
Overall,
cultured
networks—which
are
composed
produced,
fully
defined
protein—recapitulate
fibrotic
cellular
behavior
high
fidelity
enable
testing.
Язык: Английский
Development of regenerative therapies targeting fibrotic endometrium in intrauterine adhesion or thin endometrium to restore uterine function
Science China Life Sciences,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 11, 2025
Язык: Английский
Novel therapeutic strategies for Asherman's syndrome: Endometrial regeneration using menstrual blood-derived stem cells
Regenerative Therapy,
Год журнала:
2025,
Номер
29, С. 328 - 340
Опубликована: Апрель 7, 2025
Язык: Английский
A Fibronectin (FN)-Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 6, 2024
Abstract
This
study
advances
sustainable
pharmaceutical
research
for
endometriosis
by
aligning
with
the
UN
Sustainable
Development
Goals
on
health,
gender
equality,
and
responsible
consumption
in
developing
vitro
3D
cell
culture
models
of
endometriotic
pathophysiology.
Fibrosis
is
a
key
aspect
endometriosis,
yet
current
to
it
remain
limited,
especially
3D.
work
aims
bridge
translational
gap
between
fibrosis
preclinical
testing
non-hormonal
drug
candidates.
When
grown
matrix
sustainably
produced
silk
protein
functionalized
fibronectin-derived
adhesion
motif
(FN-silk),
endometrial
stromal
epithelial
cells
respond
transforming
growth
factor
beta-1
(TGF-β1)
physiological
manner
as
probed
at
mRNA
level.
For
cells,
this
response
TGF-β1
not
observed
spheroids,
while
spheroids
behave
similarly
FN-silk
networks.
Pirfenidone,
an
antifibrotic
approved
treatment
idiopathic
pulmonary
fibrosis,
reverses
TGF-β1-induced
upregulation
transcripts
involved
fibroblast-to-myofibroblast
transdifferentiation
networks,
supporting
drug’s
potential
repurposed
therapy
endometriosis.
demonstrates
how
approach
–
from
project
conceptualization
material
selection
can
be
integrated
into
women’s
health.
Table
contents
paper
presents
Endometrial
cultured
networks
showed
physiological-like
fibrotic
behavior.
Pirfenidone
was
able
reverse
,
demonstrating
model’s
suitability
screening
tool
drugs
Язык: Английский